Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Indentifying Epigenetic Biomarkers From Peripheral Blood of Advanced Osteosarcoma Patients, Who Recieve Famitinib and Camrelizumab Based on hMe-Seal Technique

NCT03919539 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03919539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03919539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Indentifying Epigenetic Biomarkers From Peripheral Blood of Advanced Osteosarcoma Patients, Who Recieve Famitinib and Camrelizumab Based on hMe-Seal Technique
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Unknown status
Start date
December 1, 2019
Completion date
December 31, 2021
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarkers for efficacy and toxicity, drug resistance to famitinib and camrelizumab